Cargando...
The molecular targets of approved treatments for pulmonary arterial hypertension
Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...
Guardado en:
| Publicado en: | Thorax |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://ncbi.nlm.nih.gov/pubmed/26219978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207170 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|